Akari Therapeutics

Intangible assets: Akari owns or controls IP around its PH1 spliceosome‑modulating payload and reported new international patent issuances in 2026. That said, all evidence of differentiation is preclinical, with no clinical or commercial validation yet. Intangible moat strength is therefore narrow and early.

Switching costs: none at present; no marketed products, no embedded workflows, and no payer relationships. Network effects: none. Cost advantages: as a virtual developer relying on CDMOs (e.g., WuXi XDC), Akari can be capital‑efficient but has no scale or procurement advantages versus larger ADC developers.

Efficient scale: oncology ADC markets are large and competitive with entrenched incumbents; efficient scale does not apply. Overall, any moat depends on translating PH1 biology into clear clinical benefit and safety superior to topoisomerase‑based Trop2 ADCs already approved, which remains uncertain.